RRP9 and pancreatic neoplasm: Thus, in addition to previously established methods of sensitizing pancreatic tumor cells to chemotherapeutic agents [49], RRP9 and its downstream effectors may be exploited as novel targets to increase PC chemosensitivity to gemcitabine.